CervoMed reports RewinD-LB trial results for neflamapimod in dementia with Lewy bodies, highlighting missed endpoints and ...

Boston-based CervoMed (CRVO) said the Phase 2b trial of its neflamapimod did not meet significant statistical thresholds for its primary endpoint of a change in the Clinical Dementia Rating Sum of ...

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...

CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...

Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks——Favorable ...

U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial. The drug, ...

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...

Cervomed Inc. executives said they intend to scrutinize low plasma drug concentrations that appeared to spoil results from the phase IIb Rewind-LB trial testing neflamapimod in patients with dementia ...

Brian Lawlor, a professor of old age psychiatry and site director of the Global Brain Health Institute at Trinity College ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Find answers to many of your Social Security questions in our new ...

Some of her diagnoses, according to her team, include dementia and Graves' disease, and she's also struggled with alcohol use. A recent four-part documentary, which aired on Lifetime in February ...

Wendy Williams’s legal guardian, Sabrina Morrissey, shared a bleak update on the former presenter’s dementia battle in a recent court filing. Morrissey, a lawyer, said the 60-year-old writer ...